Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3F to start US heart valve trial:

This article was originally published in Clinica

Executive Summary

Privately held medical device company 3F Therapeutics has gained the green light to start the US arm of a clinical trial to assess its heart valve. The aortic bioprosthesis has already been implanted in the first five patients in the European portion of the trial. "Approximately 260,000 prosthetic heart valves are implanted worldwide every year, a market currently served by much bigger companies including Medtronic, St Jude Medical, Edwards Lifesciences, Sulzer Carbomedics, and ATS Medical," says Walter Cuevas, president and CEO of Orange County, california-based 3F.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel